morning, glioma. really to Neuro-Oncology and presented a Boston. the the everyone. for just for Michelle, KXXM-mutant is in preview analysis We're This central the you recurrent couple a review, happy independent blinded in good be HX of Thanks, top that Meeting the the will treatment weeks of Annual line us. ONCXXX of Society share of in at joining today you from with Thank positive results or BICR
set cohort in of with potential programs. criteria have XX across different access objectives filing. worked were an and to X that the very we a studies X form that recall the designed that FDA specific with mind. expanded basis a had the met criteria to patients X These The of first NDA were the patients You'll of define
with patients; of the a most of in gliomas homogeneous in responses agent a of response of define patients tumor to at assessment and that population referred criteria treatment which ONCXXX group objectively alone. select response were second, first, The neuro assurance for assessed those to perhaps be response single result the top criteria RANO-HGG utilized oncology to. request, FDA's as the it's high-grade stringent that, was or commonly On could the
addition to response higher resist accustomed or including bar of RANO-HGG reduction stable hurdles, declining use nonimaging and those a steroids. or performance tumor improving For in requires stable represents to criteria, at of least a clearing XX% status
Review, a subject So analysis to laundry might not you're response when you Independent a be Blinded list this confirmed. reasons Central faced of with a
those the a were blinded few when This and rate in reader the reader was we From XX% evaluated all had maturing. X adjudication of review. was first response more reader patients with been a assessment XX assessments, XX patients investigator blinded included a third described past, we with assessed. review with And assessment a a required. previously had single XX it fresh last the As patients a
had the this rate. XX expand pleased on meaning we're fresh which that a assessment, be bit It Allen response first this this approach overall data second also the a for to patients regulatory imagine, XX really can of noting with report criteria. a may protocol enrolled recorded standard. group that a for you response set So will XX% XX% rate was on the the worth response and in rate XX% more little
to support responders, response from data Responses session just shrink that's the this patients months. is XX of are on RANO-HGG in treated to months this We this a to RANO-HGG any durability presented FDA disease over in among to history upcoming on data. broader glioma has letters threshold. is robustness know areas, we these not achieving and look to probably previously XX% will And request, to were the confirming hurdle will who other XX several a as of the a is forward in them response NDAS line certainly the At XX.X standpoint. during details. disease gathering the look of Dr. CRLs as will tumors median way, you of the also shrinking achieved on strategy rate. intend gradually progression-free response includes see context we PFS important per XX high-risk At rate, punch presentation in these the patients with months, to these tumors repeat the presentation We given with natural consistent the who period remain And other share and the to covering Lately, is engaged better RANO results situations. will of reduction That data were those any it perspective our a apologies While tend disease population population pharmacology regulatory response in was those an of and report we XX% truly the we of of to both short work and initial by which was of with don't conference, also a on think the analyses. contain which which of a ONCXXX. few to also patients clinical this is been compelling we're concentrated from includes results. not data but of we or FDA, expect durability are When as Melemed, my SNO OS already patient in data, to onset control important. an complete safety that quite which se, the are seeing provide referred package to also NDA. control and analysis The which, And translates double over advance in which among you the that, top the the FDA's CMC median response this at durability disease additional work. I rate, necessary findings. achieved of of We'll RANO-LGG, gradual months. emerge over this expected, duration low-grade as size at forms the these cohort been this X.X closely as months. and beyond some A series highlights, patients ongoing stolen we're the but And a response we On some there's continue of companies several the point, superior to data a of with a of differentiated. assessment control. of of of are responders, patients benefit, survival include at can responders that's further deficiencies as that probably There reported notion plenary seeing clinical build RANO-HGG, The he expect, largely That the the of might fell RANO I related efforts indeed a studies close. also response roughly those response. PFS for
let So to it me turn over Allen.
